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Clinical trials in heart failure (HF) tend to randomize patients
according to demographic characteristics and severity of left
ventricular dysfunction, without taking account of the precise
diagnosis. This article reviews results from recent trials suggest-
ing that the etiology of HF, and particularly whether it is ischemic
or nonischemic, may influence the long-term prognosis and the
response to treatment. Some studies, but not all, suggest that
nonischemic HF has a better prognosis than ischemic HF. The
data on the benefits of angiotensin-converting enzyme inhibitors
in ischemic versus nonischemic HF are conflicting. Carvedilol,
and recently, bisoprolol have been shown to reduce mortality in
ischemic and non-ischemic HF, whereas metoprolol has, to date,
improved prognosis only in dilated cardiomyopathy. Better re-
sponses to digoxin, amlodipine and amiodarone have been re-
ported in non-ischemic HF. There is at present no clear explana-
tion for the apparent therapeutic differences between ischemic
and nonischemic HF. Absence of a rigorous definition of “nonisch-
emic HF” in many studies makes interpretation of the results
difficult. Further studies to clarify the effects of etiology of HF on
the response to treatment could be particularly important for
preventing progression to more advanced stages, in which any
type of drug therapy may have limited value in prolonging
survival. An individualized therapeutic approach, based on etiol-
ogy of HF and possibly other factors such as plasma drug levels or
the levels of neurohormones, could result in major progress in
treating HF patients.
(J Am Coll Cardiol 1998;32:1167–72)
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In large-scale therapeutic trials in heart failure (HF), patients
are usually randomized according to demographic character-
istics and the severity of left ventricular (LV) dysfunction.
Many specialists share the view expressed by Franciosa (1) that
“there is little reason to know the precise diagnosis, since the
treatment of heart failure is essentially the same in most of
these situations.” However, recent trials suggest that the cause
of HF may influence the long-term prognosis and the response
to certain pharmacologic treatments. This review discusses the
extent to which the etiology of HF—particularly ischemic
versus nonischemic HF—influences the prognosis and the
response to drug treatment.
Epidemiology of Heart Failure
Population studies indicate that about 1% to 2% of the
population have HF and that it is predominantly a disease of
the elderly (2,3). A population-based study in the United
States reported that the prevalence of idiopathic dilated car-
diomyopathy and hypertrophic cardiomyopathy combined was
36.5 per 100,000 (4). This suggests that cardiomyopathy ac-
counts for about 2% of cases of HF. The proportion of patients
with a diagnosis of cardiomyopathy in clinical trials is much
higher, ranging from 18% (5) to 53% (6).
Pathophysiology of Ischemic and
Nonischemic HF
In ischemic heart disease (IHD) three processes can occur:
● myocardial infarction (MI), which destroys a discrete
mass of myocytes,
● chronic myocardial dysfunction, which includes hiberna-
tion and stunning and, possibly, progression to diffuse
cardiac myocyte death
● myocardial dysfunction as a result of acute, reversible
ischemia.
In most patients with dilated cardiomyopathy (DCM), the
cause of the condition is unknown or uncertain (7). Over 20%
of patients have familial disease (8). This does not appear to be
clinically distinguishable from the nonfamilial form. There is
evidence that at least some patients with DCM express anti-
myosin antibodies (9) and others express beta-receptor anti-
bodies, some of which may be physiologically active and
possess beta-agonist function (10–12). Compared with control
subjects or patients with ischemic HF, patients with DCM have
significantly greater levels of immunoreactive staining to the
inducible form of nitric oxide synthase (iNOS) in cardiac
myocytes, and to tumour necrosis factor alpha (TNFa) in
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vascular endothelium and smooth muscle cells (13). In patients
with DCM, an inflammatory reaction (triggered by an autoim-
mune or infectious event) could stimulate production of
TNFa, leading to induction of iNOS and elevation of the levels
of NO, which has a negative inotropic effect on cardiac
myocytes (14), and, at high concentrations, has cytotoxic
effects, probably through generation of free radicals (15).
In both ischemic and nonischemic HF, chronic activation of
neuroendocrine systems has harmful effects on cardiac struc-
ture and function (16–18). Oxidative stress, involving the
formation of oxygen free radicals, may play a critical role in the
pathogenesis of HF, even in the absence of coronary artery
disease (CAD) or ischemia (19–21).
Differential Diagnosis of Ischemic Versus
Nonischemic HF
In many patients, the combination of signs and symptoms of
HF with a history of angina pectoris or MI is sufficient to
support a diagnosis of ischemic HF, whereas in the absence of
significant epicardial coronary artery obstruction or an obvious
cause of HF, a diagnosis of DCM is made. An apparently
normal coronary angiogram does not rule out myocardial
ischemia because several other processes, including coronary
artery spasm, compression of subendocardial coronary vessels,
a reduction in the coronary vasodilator reserve and the pres-
ence of hypertension and a high heart rate, can produce
ischemia in the absence of detectable coronary artery obstruc-
tion (22–24).
Imaging studies can be used to assess the degree of LV
dilatation and dysfunction. Prominent localized wall motion
disorders are more characteristic of IHD, whereas diffuse
global dysfunction is more typical of DCM (25). The roles of
thallium-201 imaging and positron emission tomography for
distinguishing DCM from ischemic HF are under investigation
(26–29).
If DCM is suspected, basic biochemical screening tests to
identify potentially reversible causes (e.g., hypocalcemia, thy-
rotoxicosis, hypophosphatemia) are indicated (28).
Prognostic Differences Between Ischemic and
Nonischemic HF
A number of studies have shown that DCM has a better
response to treatment and a better prognosis than HF resulting
from IHD (30–34). Several large mortality trials in HF (35–37)
also reported that within the placebo arm, mortality was lower
in patients with nonischemic HF than in those with ischemic
HF, although other studies have reported similar mortality in
these subgroups (38–40) (Table 1). Clinical trial reports,
however, rarely explain fully how the etiology of HF was
diagnosed, and many case report forms are inadequate in this
respect. In these trials, therefore, the etiology of HF is not
known with certainty. Explanations of the apparent differences
between ischemic and nonischemic HF are therefore tentative.
The worse outcome and poorer response to treatment in
ischemic than nonischemic HF in some clinical trials may have
been an effect of patient selection. For example, patients with
IHD suitable for revascularization, who have regions of viable
myocardium that can respond to treatment, were excluded
from some trials. Alternatively, the better prognosis of nonisch-
emic HF may reflect the absence of CAD or recurrent MI, or
the lower average age of patients with DCM. For example, in
the Metoprolol in Dilated Cardiomyopathy (MDC) Trial, the
mean age of patients was 49 years (41) and in a recent series,
mean age was 43 years (42).
Data from clinical trials are in marked contrast to commu-
nity data from Framingham, which suggest that, if anything,
men who develop HF as a result of CAD do better than those
with other etiologies of HF (43).
Pharmacologic Treatment of Ischemic Versus
Nonischemic HF: Evidence From
Clinical Trials
Diuretics. There is no information on the effects of diuret-
ics on morbidity or mortality in ischemic versus nonischemic
HF. It is very difficult to obtain such information because the
dose of diuretics is frequently adjusted to maintain optimum
fluid balance, and it is not justifiable to withhold these drugs
from patients with fluid retention for the purposes of a clinical
study.
Cardiac glycosides. Pooled results from the PROVED and
RADIANCE trials indicate that digoxin increases LV ejection
fraction more in patients with DCM than in patients with IHD,
and that withdrawal of digoxin leads to significantly greater
likelihood of clinical deterioration in the DCM patients
(44,45). In the Digitalis Investigators’ Group trial (46), digoxin
was associated with a significant reduction in a combined end
point of death or hospitalization as a result of worsening HF in
patients in sinus rhythm. This benefit was somewhat greater in
patients with nonischemic etiology than in those with ischemic
etiology (46). There is no evidence that the effect of digoxin on
survival differs between ischemic and nonischemic HF.
Table 1. Mortality in IHD and non-IHD Placebo Groups of Large-
Scale HF Trials
Trial Follow-up
Mortality (%)
IHD non-IHD
V-HeFT-I (35) Mean 2.3 years 57.0 46.0
PROMISE (36) Mean 6.1 months 27.0 20.0
ACE-I meta-analysis (37) $8 weeks 27.0 18.6
CIBIS I (38) Mean 1.9 years 21.0* 20.0
US trial program (39) Median 6.5 months 8.9 6.7
PRAISE (40) 6–33 months 34.0 31.0
*Patients with a history of MI. See text for definitions of abbreviations.
V-HeFT-I, Vasodilator Heart Failure Trial I; PROMISE, Prospective Random-
ized Milrinone Survival Evaluation; CIBIS I, Cardiac Insufficiency Bisoprolol
Study I; PRAISE, Prospective Randomized Amlodipine Survival Evaluation.
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Angiotensin-converting enzyme (ACE) inhibitors. Nony et
al. (47) found that in 17 of the early ACE inhibitor trials,
mortality was significantly decreased only in the subgroup with
IHD; in the subgroup with non-IHD, the mortality reduction
was not significant. In a later meta-analysis, Garg and Yusuf
(37) reported similar reductions in mortality by ACE inhibitors
in IHD (odds ratio 0.77) and nonischemic HF (odds ratio 0.8),
but the upper confidence interval was .1 in the latter group. In
some of the pivotal trials of ACE inhibitors in HF, however, a
more favorable effect on mortality was seen in nonischemic HF
than in ischemic HF (5,48). Interpretation of these observa-
tions is difficult because of the unclear definition of “nonisch-
emic” HF in many trials. There is little information on the
effects of ACE inhibition in clearly defined DCM.
Beta-adrenergic blocking agents. Clinical trials have shown
that beta-blockers, primarily carvedilol, metoprolol and bucin-
dolol, improve hemodynamics, LV function and clinical status
in patients with HF of ischemic or nonischemic etiology (49).
These studies led to large, long-term trials to evaluate the
effects of beta-blockade on morbidity or mortality in HF. The
MDC trial enrolled only patients with DCM, mainly New York
Heart Association (NYHA) class II or class III (41). The
definition of DCM was not described in detail, but patients
with .50% obstruction of a major epicardial coronary vessel,
or clinical or histologic signs of ongoing myocarditis, were
excluded. Metoprolol had no significant effect on all-cause
mortality, but was associated with a borderline significant
reduction in a combined end point of death or the need for
heart transplantation and significant reductions in the need for
heart transplantation and in the number of hospitalizations per
patient.
The Cardiac Insufficiency Bisoprolol Study (CIBIS) inves-
tigated the effects of bisoprolol on morbidity and mortality in
patients with HF of NYHA class III or class IV (38). The most
common cause of HF was ischemia (about 55% of patients),
but patients with idiopathic DCM (about 35% of patients),
hypertension (about 5% of patients) and valvular heart disease
(about 5% of patients) were included. After a mean 1.9 years
of follow-up, survival was improved on bisoprolol therapy,
compared with placebo, only in the subgroups without a history
of MI or in those with DCM as the sole diagnosis, but not in
those with a history of MI. The mortality in the placebo arm
was about 20% in all of these subgroups. The failure to reduce
mortality in the ischemic subgroup may have reflected the
exclusion of patients suitable for revascularization who might
have had a greater potential to respond to the anti-ischemic
effects of beta-blockade than patients unsuitable for surgical
treatment.
CIBIS II was a much larger placebo-controlled trial of
bisoprolol in severe (NYHA III/IV) HF (50). The main results
were presented at a recent Congress of the European Society
of Cardiology (50a). There was a significant 32% reduction in
all cause mortality regardless of the etiology of HF.
A program of placebo-controlled trials has investigated the
effects of carvedilol on mortality and morbidity in patients with
HF resulting from CAD or nonischemic DCM (39,51–54).
Over a median follow-up of 6.5 months, overall mortality was
reduced by 65% in patients receiving carvedilol, compared
with the placebo group, and this benefit was virtually identical
in patients with ischemic or nonischemic etiology. The low
overall mortality in this trial (,10% on placebo and ,5% on
carvedilol, regardless of etiology) makes it difficult to detect
differences in mortality between patient subgroups. Carvedilol
has potent antioxidant activity (55), which may have contrib-
uted to the reduction in mortality observed in this program by
preventing cardiac myocyte dysfunction, necrosis or apoptosis.
The Australia–New Zealand HF study enrolled patients
with HF solely due to IHD (56,57). In this trial, carvedilol was
associated with a nonsignificant trend towards lower mortality
and a reduction in a combined end point of death or all-cause
hospitalization after a mean follow-up of 19 months, compared
with the placebo group. The absence of a significant effect on
mortality in this trial may have been a result of its small size
and the very mild HF and low mortality of the patients
enrolled.
Comparative trials between beta-blockers in HF are re-
quired to clarify whether the differences in outcome seen in the
studies summarized above result from patient selection or the
properties of the agents. The first such study is COMET
(Carvedilol or Metoprolol European Trial), which started in
November 1996 and is due to end in August 2000 (58). This is
a randomized double-blind trial of carvedilol (starting dose
3.125 mg b.i.d. titrated to 25 mg b.i.d.) versus metoprolol
(starting dose 5 mg b.i.d. titrated to 50 mg b.i.d.) in 3,000
patients with NYHA class II to III HF, despite conventional
therapy. Patients with HF of ischemic and nonischemic etiol-
ogy will be included. The primary end point will be all-cause
mortality. Secondary end points will include cardiovascular
deaths and changes in NYHA class.
Amiodarone. Two randomized trials of amiodarone have
been performed in HF. GESICA examined low-dose
(300 mg/day) amiodarone in severe HF (59). Overall mortality
and hospital admission for worsening HF were significantly
lower in the amiodarone group than the control group in all
patient subgroups examined. In the larger CHF-STAT trial,
amiodarone did not significantly reduce the incidence of
sudden death or prolong survival, but there was a trend toward
reduced mortality among patients with nonischemic cardiomy-
opathy (60,61).
Calcium antagonists. Studies of calcium antagonists con-
ducted before the use of ACE inhibitors became widespread
indicated that diltiazem (62) and nifedipine (63) could ad-
versely affect the prognosis of HF. More recent results with
diltiazem (64) and felodipine (65,66), in contrast, suggest no
effect on overall mortality (65). The PRAISE trial (40) showed
that among patients with nonischemic HF, amlodipine reduced
the risk of fatal and nonfatal cardiac events by 31% (p , 0.04)
and decreased the risk of death by 46% (p , 0.001), but there
was no effect on either of these end points in the group with
IHD. However, in this trial the definition of “nonischemic
dilated cardiomyopathy” was not rigorous, and patients with
undetected CAD may have been included in this group (67). A
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second trial with much more stringent criteria is being con-
ducted to test the validity of the results observed in patients
without IHD.
Conclusions
Since the introduction of ACE inhibitors, the improvement
of prognosis has become an important objective in the man-
agement of HF. There is some evidence that the etiology of HF
influences its response to beta-blockers and possibly ACE
inhibitors and calcium antagonists. The response to other
treatments with a potential benefit on prognosis (e.g., angio-
tensin II receptor antagonists) might also be dependent on
etiology. Identification of the etiology of HF might become
more important as physicians aim to select the optimum
treatment from the increasing number of options available. At
present, however, the incomplete documentation of the cause
of HF in many studies, the conflicting results in the literature
and the presence of confounding factors (e.g., the young mean
age of the patients in many trials of DCM) mean that
recommendations for the treatment of HF based on etiology
are tentative. Moreover, the lack of interest in establishing
etiology could contribute to frequent undertreatment of HF.
The conflicting reports on the benefits of ACE inhibitors in
ischemic versus nonischemic HF make it impossible to provide
firm recommendations on the use of these agents based on
etiology. Most of the evidence for the benefits of ACE
inhibition comes from patients with IHD, and the reduction of
reinfarction by ACE inhibitors applies only to this group. A
study of ACE inhibitors in clearly defined DCM would be
valuable.
Carvedilol and now also bisoprolol have been shown to
reduce mortality in both ischemic and non-ischemic HF,
whereas metoprolol has, at present, improved prognosis only
in patients with dilated cardiomyopathy. However, none of the
beta-blocker studies have been designed to compare long-term
outcome in HF of different causes. To answer this question and
to evaluate possible differences between various types of
beta-blockers requires further trials such as COMET.
The results obtained in the nonischemic subgroup of the
PRAISE trial are the only report of a reduction in mortality in
HF by a calcium antagonist. Patients with hypertensive HF
might benefit from calcium antagonists via a reduction in
systemic blood pressure, but this suggestion has not been
tested in a randomized controlled trial.
The selection of the initial drug therapy based on etiology
could be of particular importance at the early (NYHA class I
to II) stages of HF. Identification of pathogenic factors, such as
immunologic processes, inflammation with cytokine activation,
neurohormone levels and abnormalities of serum lipids, fibrin-
ogen and thrombophilic factors would allow a more selective,
targeted intervention with appropriate drugs. If an ischemic
etiology is established, preventive therapy with lipid-lowering
agents and in future antibiotics to eliminate Chlamydia (68)
could be as important in preventing further progression of HF
as the anti-HF drugs used today. On the other hand, growth
hormone or insulinlike growth factor may be an appropriate
treatment in patients with cardiomyopathy (69). Whether
beta-blockers or ACE inhibitors will have an advantage as the
first intervention remains to be studied, since most patients
received ACE inhibition as part of their background therapy in
the beta-blocker trials. Controlled comparative trials such as
CARMEN (Carvedilol ACE inhibitor Remodelling Mild HF
Evaluation), which will evaluate carvedilol versus enalapril
versus carvedilol 1 enalapril in 450 patients with mild HF (70),
are therefore of considerable practical interest.
As more therapeutic options are developed, individualized
drug selection for patients with HF might become possible.
Furthermore, individually adapted rather than schematic dos-
age regimens based on clinical (heart rate, heart rate variabil-
ity, blood pressure) and laboratory (natriuretic peptides, cyto-
kines, drug level measurements) criteria could contribute to
improved efficacy and better long-term tolerance of drugs in
HF. An early and precise diagnosis of the etiology of heart
failure should be encouraged not only in future clinical trials
but also in everyday patient management.
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